Effect of the GLP ‐1 receptor agonist exenatide on pro‐inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double‐blinded, placebo‐controlled clinical trial
Alcohol, Clinical and Experimental Research · 2025
DOI: 10.1111/acer.70110 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alcohol, Clinical and Experimental Research, 2025. Verfasst von Malthe E B Hviid und 10 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatric Centre Copenhagen, Mental Health Services in the Capitol Region of Denmark, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Alcoholism. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: P.A. Messerschmidt og Hustrus Fond, Lundbeck Foundation, Slagtermester Max Worzner og hustru Inger Worzners mindelegat.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Background
Alcohol use disorder (AUD) has been associated with inflammation, metabolic syndrome, and increased risk of all‐cause mortality. This study aimed to compare the pro‐inflammatory and metabolic biomarker profiles in individuals with AUD with individuals without AUD, and to evaluate the effect of exenatide on these biomarkers in individuals with AUD.
Methods
Serum concentrations of 25 biomarkers (interferon‐γ [IFN‐γ], tumor necrosis factor‐α [TNF‐α], interleukin (IL)‐1β, IL‐2, IL‐4, IL‐6, IL‐8, IL‐10, IL‐12p70, IL‐13, monocyte chemoattractant protein‐1 [MCP‐1], C‐peptide, gastric inhibitory polypeptide [GIP], glucagon‐like peptide [GLP‐1], glucagon, insulin, leptin, pancreatic polypeptide [PP], adiponectin, high sensitivity C‐reactive protein [hsCRP], fibroblast growth factor 21 [FGF‐21], total cholesterol [CHOL], high‐density lipoprotein [HDL], low‐density lipoprotein [LDL], and triglycerides [TG]) from individuals with AUD were measured at baseline and after 26 weeks of treatment with the GLP‐1 receptor agonist (GLP‐1RA) exenatide once‐weekly or placebo, using multiplexed immunoassays, enzyme‐linked immunosorbent assay (ELISA), and line immunoassays. Serum samples from 23 individuals with no record of AUD or treatment with a GLP‐1RA were measured once for comparison with individuals with AUD.
Results
IL‐6 (1.56 vs. 0.62 pg/mL), hsCRP (3.30 vs. 1.34 mg/L), and FGF‐21 (1794.97 vs. 306.11 pg/mL) were significantly higher, whereas GIP (63.06 vs. 111.07 pg/mL) was significantly lower in individuals with AUD ( n = 124) than in those without AUD ( n = 23). No significant changes in biomarker levels were observed after treatment with exenatide ( n = 40) compared with treatment with placebo ( n = 37).
Conclusion
Our findings support the well‐established link between AUD and inflammation. However, treatment with the GLP‐1 receptor agonist exenatide did not impact pro‐inflammatory and metabolic biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Psychiatric Centre Copenhagen, Mental Health Services in the Capitol Region of Denmark, Copenhagen, Denmark.
- Department of Clinical Immunology, Zealand University Hospital, Koege, Denmark.
- Institute of Biological Psychiatry, Mental Health Services Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Immunology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark.
- Steno Diabetes Center Copenhagen, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Lea A N Christoffersen, Mette K Klausen, Thorsten Brodersen, Ole B Pedersen, Sisse R Ostrowski, Mathias E Jensen, Tina Vilsbøll, Anders Fink-Jensen
Förderung
- P.A. Messerschmidt og Hustrus Fond
- Lundbeck Foundation
- Slagtermester Max Worzner og hustru Inger Worzners mindelegat
- Grosserer L.F. Foghts Fond
- The A.P. Moeller Foundation
- The Augustinus Foundation
- The Research Foundation, Capital Region of Denmark
- The Ivan Nielsen Foundation
Zitieren
APA
Hviid, M. E. B., Christoffersen, L. A. N., Klausen, M. K., Brodersen, T., Pedersen, O. B., Ostrowski, S. R., Larsen, M. H., Kongstad, M., Jensen, M. E., Vilsbøll, T., & Fink-Jensen, A. (2025). Effect of the GLP ‐1 receptor agonist exenatide on pro‐inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double‐blinded, placebo‐controlled clinical trial. Alcohol, Clinical and Experimental Research. https://doi.org/10.1111/acer.70110
Vancouver
Hviid MEB, Christoffersen LAN, Klausen MK, Brodersen T, Pedersen OB, Ostrowski SR, et al. Effect of the GLP ‐1 receptor agonist exenatide on pro‐inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double‐blinded, placebo‐controlled clinical trial. Alcohol, Clinical and Experimental Research. 2025. doi:10.1111/acer.70110
BibTeX
@article{Hviid2025,
author = {Hviid, Malthe E B and Christoffersen, Lea A N and Klausen, Mette K and Brodersen, Thorsten and Pedersen, Ole B and Ostrowski, Sisse R and Larsen, Margit H and Kongstad, Mette and Jensen, Mathias E and Vilsbøll, Tina and Fink-Jensen, Anders},
title = {Effect of the GLP ‐1 receptor agonist exenatide on pro‐inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double‐blinded, placebo‐controlled clinical trial},
journal = {Alcohol, Clinical and Experimental Research},
year = {2025},
doi = {10.1111/acer.70110}
}
EUVIMED